OpenNashEarnings

Pharmaceuticals · Nasdaq: SNY

Sanofi earnings: results, call transcripts & KPI history

2 quarters · fiscal year ends December · next results expected around 28 Jan 2027

Investor relations ↗SEC filings ↗KPIs as CSV

Latest: Q3 2026

Sanofi expanded its Regeneron alliance with four long-acting immunology antibodies to prepare for Dupixent's loss of exclusivity, while cutting pipeline programs and divesting mature medicines.

Demand for Dupixent and the newer launches drove the quarter. Dupixent is now treating more than 1.5 million patients and is still led by demand, with only about 20% of atopic dermatitis patients on advanced therapies. Launches such as ALTUVIIIO, Ayvakit and Rezurock grew strongly, and three new rare-disease medicines reached patients in China. Vaccines slipped because flu deliveries shifted into the fourth quarter and the CDC placed a smaller Beyfortus order. Sanofi also cleared out part of its legacy portfolio through a Cheplapharm partnership.

Read the Q3 2026 summary →

Quarters

KPI history

20-F filings